The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET): A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data.
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis
Research Funding - Novartis
James C. Yao
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Emilio Bajetta
No relevant relationships to disclose
Mounir Aout
Employment or Leadership Position - Novartis
Bert Bakker
Employment or Leadership Position - Novartis
John D. Hainsworth
No relevant relationships to disclose
Philippe B. Ruszniewski
Employment or Leadership Position - Ipsen
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Ipsen; Novartis; Pfizer
Eric Van Cutsem
Research Funding - Novartis
Kjell E. Oberg
Consultant or Advisory Role - Camurus ; Ipsen; Novartis
Marianne E. Pavel
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer